These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9379347)

  • 1. Bioadhesive microspheres for ophthalmic administration of acyclovir.
    Genta I; Conti B; Perugini P; Pavanetto F; Spadaro A; Puglisi G
    J Pharm Pharmacol; 1997 Aug; 49(8):737-42. PubMed ID: 9379347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonpolymeric nanoassemblies for ocular administration of acyclovir: pharmacokinetic evaluation in rabbits.
    Stella B; Arpicco S; Rocco F; Burgalassi S; Nicosia N; Tampucci S; Chetoni P; Cattel L
    Eur J Pharm Biopharm; 2012 Jan; 80(1):39-45. PubMed ID: 22008147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and characterization of sponge-like acyclovir ocular minitablets.
    Refai H; Tag R
    Drug Deliv; 2011 Jan; 18(1):38-45. PubMed ID: 20804440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of drug loading and type of ointment base on the in vitro performance of acyclovir ophthalmic ointment.
    Al-Ghabeish M; Xu X; Krishnaiah YS; Rahman Z; Yang Y; Khan MA
    Int J Pharm; 2015 Nov; 495(2):783-91. PubMed ID: 26343911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucoadhesive microspheres for gastroretentive delivery of acyclovir: in vitro and in vivo evaluation.
    Dhaliwal S; Jain S; Singh HP; Tiwary AK
    AAPS J; 2008 Jun; 10(2):322-30. PubMed ID: 18523891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovir.
    Fresta M; Fontana G; Bucolo C; Cavallaro G; Giammona G; Puglisi G
    J Pharm Sci; 2001 Mar; 90(3):288-97. PubMed ID: 11170022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections.
    Katragadda S; Gunda S; Hariharan S; Mitra AK
    Int J Pharm; 2008 Jul; 359(1-2):15-24. PubMed ID: 18472234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits.
    Attia IA; El-Gizawy SA; Fouda MA; Donia AM
    AAPS PharmSciTech; 2007 Dec; 8(4):E106. PubMed ID: 18181527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastroretentive drug delivery system of acyclovir-loaded alginate mucoadhesive microspheres: formulation and evaluation.
    Shadab ; Ahuja A; Khar RK; Baboota S; Chuttani K; Mishra AK; Ali J
    Drug Deliv; 2011 May; 18(4):255-64. PubMed ID: 21110695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microparticulate drug delivery systems.
    Genta I; Perugini P; Pavanetto F; Modena T; Conti B; Muzzarelli RA
    EXS; 1999; 87():305-13. PubMed ID: 10906969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved intraocular bioavailability of ganciclovir by mucoadhesive polymer based ocular microspheres: development and simulation process in Wistar rats.
    Kapanigowda UG; Nagaraja SH; Ramaiah B; Boggarapu PR
    Daru; 2015 Oct; 23():49. PubMed ID: 26497653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nano and microparticulate chitosan-based systems for antiviral topical delivery.
    Calderón L; Harris R; Cordoba-Diaz M; Elorza M; Elorza B; Lenoir J; Adriaens E; Remon JP; Heras A; Cordoba-Diaz D
    Eur J Pharm Sci; 2013 Jan; 48(1-2):216-22. PubMed ID: 23159663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of liposome-encapsulated acyclovir with acyclovir ointment: ocular pharmacokinetics in rabbits.
    Chetoni P; Rossi S; Burgalassi S; Monti D; Mariotti S; Saettone MF
    J Ocul Pharmacol Ther; 2004 Apr; 20(2):169-77. PubMed ID: 15117573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption.
    Law SL; Huang KJ; Chiang CH
    J Control Release; 2000 Jan; 63(1-2):135-40. PubMed ID: 10640587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eudragit microparticles as a possible tool for ophthalmic administration of acyclovir.
    Cortesi R; Ajanji SC; Sivieri E; Manservigi M; Fundueanu G; Menegatti E; Esposito E
    J Microencapsul; 2007 Aug; 24(5):445-56. PubMed ID: 17578734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preparation and evaluation of a novel gastric mucoadhesive sustained-release acyclovir microsphere.
    Liu H; Pan W; Ke P; Dong Y; Ji L
    Drug Dev Ind Pharm; 2010 Sep; 36(9):1098-105. PubMed ID: 20545521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Floating properties and release characteristics of hollow microspheres of acyclovir.
    Junyaprasert VB; Pornsuwannapha S
    Drug Deliv; 2008 Jun; 15(5):331-41. PubMed ID: 18763164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of mucoadhesive microspheres of acyclovir with enhanced bioavailability.
    Tao Y; Lu Y; Sun Y; Gu B; Lu W; Pan J
    Int J Pharm; 2009 Aug; 378(1-2):30-6. PubMed ID: 19465102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulation and process factors influencing product quality and in vitro performance of ophthalmic ointments.
    Xu X; Al-Ghabeish M; Rahman Z; Krishnaiah YS; Yerlikaya F; Yang Y; Manda P; Hunt RL; Khan MA
    Int J Pharm; 2015 Sep; 493(1-2):412-25. PubMed ID: 26231106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of chitosan glutamate, carbomer 974P, and EDTA on the in vitro Caco-2 permeability and oral pharmacokinetic profile of acyclovir in rats.
    Merzlikine A; Rotter C; Rago B; Poe J; Christoffersen C; Thomas VH; Troutman M; El-Kattan A
    Drug Dev Ind Pharm; 2009 Sep; 35(9):1082-91. PubMed ID: 19294548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.